CenterWatch Announces: Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges — March. 23 and March. 25, 2021 Share Article Can one’s clinical trials’ data integrity controls withstand FDA scrutiny? Stay compliant and avoid 483s or warning letters. Register today. WCG CenterWatch Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges A Virtual Workshop Presented by CenterWatch and Cerulean Associates LLC Tuesday, March 23 and Thursday, March 25, 2021, 10:00 a.m.-4:30 p.m. EDT Is the FDA’s increasing scrutiny on clinical trials’ data integrity producing a data migraine? One must establish internal competency and assessment programs; otherwise, one can expect 483s and warning letters to come rolling in.